Drug Profile
Rifasutenizol - TenNor Therapeutics
Alternative Names: TNP-2198Latest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator Cumbre Pharmaceuticals
- Developer TenNor Therapeutics
- Class Antibacterials; Drug conjugates; Nitroimidazoles; Rifamycins
- Mechanism of Action DNA synthesis inhibitors; Protein 50S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Helicobacter infections
- No development reported Bacterial vaginosis
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for phase-I development in Helicobacter-infections(In the elderly, In adults) in China (PO, Capsule)
- 18 May 2023 Phase-III clinical trials in Helicobacter infections (Combination therapy, In adults, In the elderly) in China (PO) (NCT05857163)
- 12 May 2023 TenNor Therapeutics plans a phase III trial for Helicobacter infections (Combination therapy) in China (PO, Capsule) in May 2023 (NCT05857163)